B-intervention	0	7	Focused
I-intervention	8	17	microwave
I-intervention	18	31	thermotherapy
O	32	35	for
O	36	48	preoperative
O	49	58	treatment
O	59	61	of
O	62	70	invasive
O	71	77	breast
O	78	84	cancer
O	84	85	:
O	86	87	a
O	88	94	review
O	95	97	of
O	98	106	clinical
O	107	114	studies
O	114	115	.

O	116	128	Preoperative
O	129	136	focused
O	137	146	microwave
O	147	160	thermotherapy
O	161	162	(
O	162	165	FMT
O	165	166	)
O	167	169	is
O	170	171	a
O	172	181	promising
O	182	188	method
O	189	192	for
O	193	201	targeted
O	202	211	treatment
O	212	214	of
O	215	221	breast
O	222	228	cancer
O	229	234	cells
O	234	235	.

O	236	243	Results
O	244	246	of
O	247	251	four
O	252	257	multi
O	257	258	-
O	258	271	institutional
O	272	280	clinical
O	281	288	studies
O	289	291	of
O	292	304	preoperative
O	305	308	FMT
O	309	312	for
O	313	321	treating
O	322	330	invasive
O	331	341	carcinomas
O	342	344	in
O	345	348	the
O	349	355	intact
O	356	362	breast
O	363	366	are
O	367	375	reviewed
O	375	376	.

O	377	387	Externally
O	388	395	applied
O	396	400	wide
O	400	401	-
O	401	406	field
O	407	415	adaptive
O	416	422	phased
O	422	423	-
O	423	428	array
O	429	432	FMT
O	433	436	has
O	437	441	been
O	442	454	investigated
O	455	459	both
O	460	462	as
O	463	464	a
O	465	477	preoperative
O	478	482	heat
O	482	483	-
O	483	488	alone
O	489	497	ablation
O	498	507	treatment
O	508	511	and
O	512	514	as
O	515	516	a
O	517	528	combination
O	529	538	treatment
O	539	543	with
O	544	556	preoperative
O	557	570	anthracycline
O	570	571	-
O	571	576	based
O	577	589	chemotherapy
O	590	593	for
O	594	600	breast
O	601	607	tumors
O	608	615	ranging
O	616	618	in
O	619	629	ultrasound
O	629	630	-
O	630	638	measured
O	639	643	size
O	644	648	from
O	649	650	0
O	650	651	.
O	651	652	8
O	653	655	to
O	656	657	7
O	657	658	.
O	658	659	8
O	660	662	cm
O	662	663	.

O	664	666	In
O	667	672	phase
O	673	674	I
O	674	675	,
B-iv-bin-abs	676	681	eight
O	682	684	of
B-intervention-participants	685	688	ten
O	689	690	(
O	690	692	80
O	692	693	%
O	693	694	)
O	695	703	patients
O	704	713	receiving
O	714	715	a
O	716	722	single
O	723	726	low
O	727	731	dose
O	732	734	of
O	735	738	FMT
O	739	744	prior
O	745	747	to
O	748	757	receiving
O	758	768	mastectomy
O	769	772	had
O	773	774	a
B-outcome	775	782	partial
I-outcome	783	788	tumor
I-outcome	789	797	response
O	798	808	quantified
O	809	811	by
O	812	818	either
O	819	829	ultrasound
O	830	842	measurements
O	843	845	of
O	846	851	tumor
O	852	858	volume
O	859	868	reduction
O	869	871	or
O	872	874	by
O	875	885	pathologic
O	886	890	cell
O	891	895	kill
O	895	896	.

O	897	899	In
O	900	905	phase
O	906	908	II
O	908	909	,
O	910	913	the
O	914	917	FMT
O	918	925	thermal
O	926	930	dose
O	931	934	was
O	935	944	increased
O	945	947	to
O	948	957	establish
O	958	959	a
O	960	969	threshold
O	970	974	dose
O	975	977	to
O	978	984	induce
O	985	988	100
O	988	989	%
O	990	1000	pathologic
O	1001	1006	tumor
O	1007	1011	cell
O	1012	1016	kill
O	1017	1020	for
O	1021	1029	invasive
O	1030	1040	carcinomas
O	1041	1046	prior
O	1047	1049	to
B-control	1050	1056	breast
I-control	1056	1057	-
I-control	1057	1067	conserving
I-control	1068	1075	surgery
I-control	1076	1077	(
I-control	1077	1080	BCS
I-control	1080	1081	)
O	1081	1082	.

O	1083	1085	In
O	1086	1087	a
O	1088	1098	randomized
O	1099	1104	study
O	1105	1108	for
B-eligibility	1109	1117	patients
I-eligibility	1118	1122	with
I-eligibility	1123	1128	early
I-eligibility	1128	1129	-
I-eligibility	1129	1134	stage
I-eligibility	1135	1143	invasive
I-eligibility	1144	1150	breast
I-eligibility	1151	1157	cancer
O	1157	1158	,
O	1159	1161	of
O	1162	1167	those
O	1168	1176	patients
O	1177	1186	receiving
O	1187	1199	preoperative
O	1200	1203	FMT
O	1204	1206	at
O	1207	1215	ablative
O	1216	1228	temperatures
O	1228	1229	,
B-iv-bin-abs	1230	1231	0
O	1232	1234	of
B-intervention-participants	1235	1237	34
O	1238	1239	(
B-iv-bin-percent	1239	1240	0
I-iv-bin-percent	1240	1241	%
O	1241	1242	)
O	1243	1251	patients
O	1252	1255	had
B-outcome	1256	1264	positive
I-outcome	1265	1270	tumor
I-outcome	1271	1278	margins
O	1278	1279	,
O	1280	1287	whereas
B-outcome	1288	1296	positive
I-outcome	1297	1304	margins
O	1305	1313	occurred
O	1314	1316	in
B-cv-bin-abs	1317	1318	4
O	1319	1321	of
B-control-participants	1322	1324	41
O	1325	1326	(
B-cv-bin-percent	1326	1327	9
I-cv-bin-percent	1327	1328	.
I-cv-bin-percent	1328	1329	8
I-cv-bin-percent	1329	1330	%
O	1330	1331	)
O	1332	1334	of
O	1335	1343	patients
O	1344	1353	receiving
O	1354	1357	BCS
O	1358	1363	alone
O	1364	1365	(
O	1365	1366	P
O	1367	1368	=
O	1369	1370	0
O	1370	1371	.
O	1371	1373	13
O	1373	1374	)
O	1374	1375	.

O	1376	1378	In
O	1379	1380	a
O	1381	1391	randomized
O	1392	1397	study
O	1398	1401	for
O	1402	1410	patients
O	1411	1415	with
O	1416	1421	large
O	1422	1428	tumors
O	1428	1429	,
O	1430	1435	based
O	1436	1438	on
O	1439	1449	ultrasound
O	1450	1462	measurements
O	1463	1466	the
B-outcome	1467	1473	median
I-outcome	1474	1479	tumor
I-outcome	1480	1486	volume
I-outcome	1487	1496	reduction
O	1497	1500	was
B-iv-bin-percent	1501	1503	88
I-iv-bin-percent	1503	1504	.
I-iv-bin-percent	1504	1505	4
I-iv-bin-percent	1505	1506	%
O	1507	1508	(
O	1508	1509	n
O	1510	1511	=
B-iv-bin-percent	1512	1514	14
O	1514	1515	)
O	1516	1519	for
O	1520	1528	patients
O	1529	1538	receiving
O	1539	1542	FMT
O	1543	1546	and
O	1547	1558	neoadjuvant
O	1559	1571	chemotherapy
O	1571	1572	,
O	1573	1581	compared
O	1582	1586	with
B-cv-bin-percent	1587	1589	58
I-cv-bin-percent	1589	1590	.
I-cv-bin-percent	1590	1591	8
I-cv-bin-percent	1591	1592	%
O	1593	1594	(
O	1594	1595	n
O	1596	1597	=
B-cv-bin-abs	1598	1600	10
O	1600	1601	)
O	1602	1611	reduction
O	1612	1614	in
O	1615	1618	the
O	1619	1630	neoadjuvant
O	1631	1643	chemotherapy
O	1643	1644	-
O	1644	1649	alone
O	1650	1653	arm
O	1654	1655	(
O	1655	1656	P
O	1657	1658	=
O	1659	1660	0
O	1660	1661	.
O	1661	1664	048
O	1664	1665	)
O	1665	1666	.

O	1667	1671	Wide
O	1671	1672	-
O	1672	1677	field
O	1678	1686	adaptive
O	1687	1693	phased
O	1693	1694	-
O	1694	1699	array
O	1700	1703	FMT
O	1704	1707	can
O	1708	1710	be
O	1711	1717	safely
O	1718	1730	administered
O	1731	1733	in
O	1734	1735	a
O	1736	1748	preoperative
O	1749	1756	setting
O	1756	1757	,
O	1758	1761	and
O	1762	1766	data
O	1767	1771	from
O	1772	1782	randomized
O	1783	1790	studies
O	1791	1798	suggest
O	1799	1803	both
O	1804	1805	a
O	1806	1815	reduction
O	1816	1818	in
O	1819	1827	positive
O	1828	1833	tumor
O	1834	1841	margins
O	1842	1844	as
O	1845	1846	a
O	1847	1851	heat
O	1851	1852	-
O	1852	1857	alone
O	1858	1867	treatment
O	1868	1871	for
O	1872	1877	early
O	1877	1878	-
O	1878	1883	stage
O	1884	1890	breast
O	1891	1897	cancer
O	1898	1901	and
O	1902	1903	a
O	1904	1913	reduction
O	1914	1916	in
O	1917	1922	tumor
O	1923	1929	volume
O	1930	1934	when
O	1935	1939	used
O	1940	1942	in
O	1943	1954	combination
O	1955	1959	with
O	1960	1973	anthracycline
O	1973	1974	-
O	1974	1979	based
O	1980	1992	chemotherapy
O	1993	1996	for
O	1997	2005	patients
O	2006	2010	with
O	2011	2016	large
O	2017	2023	breast
O	2024	2030	cancer
O	2031	2037	tumors
O	2037	2038	.

O	2039	2045	Larger
O	2046	2056	randomized
O	2057	2064	studies
O	2065	2068	are
O	2069	2077	required
O	2078	2080	to
O	2081	2087	verify
O	2088	2093	these
O	2094	2105	conclusions
O	2105	2106	.
